Platelet-rich plasma is not one treatment with one evidence base. What the platelets are injected into — a tendon, or a joint space — changes the trial designs, the outcome measures, and the results. The clearest demonstration is that level I evidence supports PRP in rotator cuff tendinopathies and tears while contradictory level I evidence discourages its use in patellar and Achilles tendinopathies and tears [1].
Both of those are tendon targets. If the evidence splits that sharply within a single tissue type, a general claim that “PRP works” cannot survive contact with a specific diagnosis.
Why the target changes the question
Tendon targets
A tendon injection is aimed at tendon substance and the tendon-bone interface, where repetitive load and accumulated microtrauma are the working model of the problem. The outcome measures in those trials are usually a pain score and a limb-specific function score, read at short, mid, and long follow-up.
Joint-space targets
An intra-articular injection is aimed at the joint space, where synovial irritation, the joint fluid environment, and mechanical factors inside the joint contribute to symptoms. Different tissue, different mechanism, different endpoints — and therefore a separate body of evidence that should not be read across from the tendon literature.
Across musculoskeletal medicine as a whole, level I evidence has been reported supporting PRP in osteoarthritis, epicondylitis, bursitis, compressive neuropathy, plantar fasciitis, muscular injuries, and osteochondral lesions [1]. The same review notes that spinal and hand conditions have limited research available, and that the overall evidence continues to produce conflicting results [1].
What the tendon evidence shows, site by site
Rotator cuff
In a 2025 review comparing PRP with corticosteroid injection across tendinopathies, short-term pain and function were more improved after PRP in patients with rotator cuff tendinopathy, but that effect was not sustained long-term [2]. A separate 2025 systematic review and meta-analysis of 27 randomized controlled trials in 1,779 patients found no group difference in pain or function at one month in patients with rotator cuff injury, and greater improvement in the visual analogue pain score with PRP at three months (OR −1.64, 95% CI −2.97 to −0.31, p = 0.02) [3].
Lateral epicondylitis and gluteal tendinopathy
The same 2025 comparative review reported that PRP showed longer-term effectiveness over corticosteroids in gluteal tendinopathies and lateral epicondylitis, but not in the short term [2]. That is the reverse of the rotator cuff pattern, in the same review, from the same comparison.
Plantar fasciitis and tenosynovitis
In the 27-trial meta-analysis, patients with plantar fasciitis showed no significant difference in pain or AOFAS scores between PRP and corticosteroid at one and three months, but at six months the PRP group had significantly better scores on both [3]. In patients with tenosynovitis, the pain score was lower in the corticosteroid group at one month, and superior in the PRP group at six months (OR −0.72, 95% CI −1.04 to −0.40, p < 0.00001) [3].
The authors’ overall conclusion was that PRP’s mid-term efficacy is superior to that of corticosteroid in tendinopathy, while long-term efficacy remains to be verified clinically [3].
What this means for a knee
Patients asking about an alternative to knee replacement are asking a joint-space question, not a tendon question, and the tendon results above do not transfer to it. For advanced knee osteoarthritis, platelet-rich plasma is framed the way the trial authors framed it: as a safe bridge therapy prior to arthroplasty.
No orthobiologic offered at our orthobiologics service is claimed to regrow or regenerate cartilage. Where a patient is on that timeline, and whether a bridge is even useful for them, is a clinical determination rather than a marketing one.
How the target is chosen
Three questions come first: which structure is most likely driving the pain now, what has already been tried and for how long, and what outcome timeline is reasonable for that specific target. Only after those are answered does the choice among PRP, intraosseous or subchondral approaches, bone marrow aspirate concentrate, and Lipogems become meaningful.
Our terrain-first approach adds a fourth consideration: the metabolic environment the tissue is being asked to repair in, which affects the response to any biologic regardless of where it is placed.
Frequently asked questions
Is PRP better for a tendon or for a joint?
That question has no single answer, because the trials are run separately by anatomic site and report different results. Level I evidence supports PRP in rotator cuff tendinopathy and tears while contradictory level I evidence discourages it in patellar and Achilles tendinopathies and tears, so the site matters more than the category. Which target applies to you is decided at examination, described on our joint dysfunction page.
How long after a PRP injection should a difference be expected?
In the pooled comparison against corticosteroid, differences appeared at different time points by condition — three months in rotator cuff injury, six months in plantar fasciitis and tenosynovitis — and the authors state that long-term efficacy remains to be verified. Reading trial endpoints rather than headlines is covered in the Regen.MD library.
Does PRP rebuild cartilage in an arthritic knee?
No. For advanced knee osteoarthritis, PRP is framed the way the trial authors framed it — as a safe bridge therapy prior to arthroplasty — and no orthobiologic offered here is claimed to regrow or regenerate cartilage. Those distinctions are reviewed at evaluation by Dr. Gurpreet Singh Padda, MD, MBA, MHP.
What if both a tendon and a joint are involved?
Mixed presentations are common in the shoulder, elbow, hip, and knee, and the aim is to identify which structure is dominant now rather than to inject everything at once. That determination is made in person at our St. Louis clinic.
Key takeaways
- Level I evidence supports PRP in rotator cuff tendinopathies and tears, while contradictory level I evidence discourages it in patellar and Achilles tendinopathies and tears — both tendon targets.
- Tendon and joint-space injections are studied separately with different endpoints; results do not transfer between them.
- In 27 randomized trials covering 1,779 patients, PRP beat corticosteroid at three months in rotator cuff injury and at six months in plantar fasciitis and tenosynovitis, with long-term efficacy still unverified.
- In lateral epicondylitis and gluteal tendinopathy the pattern reverses: PRP showed longer-term rather than short-term advantage over corticosteroid.
- For advanced knee osteoarthritis, PRP is a bridge therapy prior to arthroplasty. No orthobiologic here is claimed to rebuild lost cartilage.
Medically reviewed by Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed August 2026.
This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary, and not every patient is a candidate for the therapies described. Do not start, stop, or change any treatment without consulting your physician. Orthobiologic therapies are not FDA-approved for this indication and are provided as part of physician-directed care.
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
Sources
- Pretorius J, et al. “Current Status and Advancements in Platelet-Rich Plasma Therapy.” Cureus, 2023;15(10):e47176. https://pmc.ncbi.nlm.nih.gov/articles/PMC10652151/
- Modi K, Jain Y, Shah R, Ranga R. “Evaluating Efficacy of Platelet-Rich Plasma versus Corticosteroids in Management of Tendinopathies.” Georgetown Medical Review, 2025;9(1). https://doi.org/10.52504/001c.141338
- Ye X, Yuan Y, Kuang X, Qiu H, Tan L, et al. “Platelet-rich plasma and corticosteroid injection for tendinopathy: a systematic review and meta-analysis.” BMC Musculoskeletal Disorders, 2025. https://pubmed.ncbi.nlm.nih.gov/40200209/